The cardiovascularmarkers copeptin and highsensitive C-reactive protein decrease following specific therapy for primary aldosteronism

Journal of Hypertension

Volumn 34, Issue 10, 2016, Pages 2066-2073

  Remde, Hanna ^a   Dietz, Anna ^b   Emeny, Rebecca ^c   Riester, Anna ^b   Peters, Annette ^c,d   De Las Heras Gala, Tonia ^c   Then, Cornelia ^b   Seissler, Jochen ^b   Beuschlein, Felix ^b   Reincke, Martin ^b   Quinkler, Marcus ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e Endocrinology in Charlottenburg   (Germany)

Author keywords

Adrenalectomy; Arginine vasopressin; Hyperaldosteronism; Mineralocorticoid receptor antagonist

Indexed keywords

C REACTIVE PROTEIN; COPEPTIN; BIOLOGICAL MARKER; GLYCOPEPTIDE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FLUOROIMMUNOASSAY; FOLLOW UP; HUMAN; HYPOKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL TRIAL; HYPERALDOSTERONISM; METABOLISM; MULTICENTER STUDY; REGISTER; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGED; BIOMARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; GLYCOPEPTIDES; HUMANS; HYPERALDOSTERONISM; HYPOKALEMIA; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SEX FACTORS;

EID: 85027917566     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001041     Document Type: Article

References (43)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380:2095-2128.
2. D'Agostino RB, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart 2013; 8:11-23.
3. Epstein FH, Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999; 340:115-126.
4. Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-Aged men results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237-242.
5. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPICNorfolk prospective population study 1993-2003. Atherosclerosis 2006; 187:415-422.
6. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem 2008; 54:335-342.
7. Morgenthaler NG. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52:112-119.
8. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states. J Clin Endocrinol Metab 2011; 96:1046-1052.
9. Dobsa L, Cullen Edozien K. Copeptin and its potential role in diagnosis and prognosis of various diseases. Biochem Medica 2013; 23:172-192.
10. Łukaszyk E, Małyszko J. Copeptin: pathophysiology and potential clinical impact. Adv Med Sci 2015; 60:335-341.
11. Sun H, Sun T, Ma B, Yang B, Zhang Y, Huang D, et al. Prediction of allcause mortality with copeptin in cardio-cerebrovascular patients: A meta-Analysis of prospective studies. Peptides 2015; 69:9-18.
12. Tasevska I, Enhörning S, Persson M, Nilsson PM, Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart 2016; 102:127-132.
13. Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: A review of the prevalence of primary aldosteronism in prehypertension and hypertension. Eur J Endocrinol 2015; 172:R191-R203.
14. Milliez P, Girerd X, Plouin P-F, Blacher J, Safar ME, Mourad J-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
15. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: Results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94:1125-1130.
16. Wu V-C, Huang K-H, Peng K-Y, Tsai Y-C, Wu C-H, Wang S-M, et al. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. Sci Rep 2015; 5:11396.
17. Nogueira-Silva L, Blanchard A, Curis E, Lorthioir A, Zhygalina V, Bergerot D, et al. Deciphering the role of vasopressin in primary aldosteronism. J Clin Endocrinol Metab 2015; 100:3297-3303.
18. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94:869-875.
19. Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12:43-48.
20. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
21. Klüppelholz B, Thorand B, Koenig W, de las Heras Gala T, Meisinger C, Huth C, et al. Association of subclinical inflammation with deterioration of glycaemia before the diagnosis of type 2 diabetes: The KORA S4/F4 study. Diabetologia 2015; 58:2269-2277.
22. Rathmann W, Strassburger K, Heier M, Holle R, Thorand B, Giani G, et al. Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 2009; 26:1212-1219.
23. Then C, Kowall B, Lechner A, Meisinger C, Heier M, Koenig W, et al. Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study. Acta Diabetol 2015; 52:103-112.
24. Pearson TA. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
25. Weigel M, Riester A, Hanslik G, Lang K, Willenberg HS, Endres S, et al. Postsaline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. Eur J Endocrinol 2015; 172:443-450.
26. Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn Registry. Eur J Endocrinol 2015; 173:655-675.
27. Catena C, Colussi G, Marzano L, Sechi L. Aldosterone and the heart: From basic research to clinical evidence. Horm Metab Res 2012; 44:181-187.
28. Petramala L, Pignatelli P, Carnevale R, Zinnamosca L, Marinelli C, Settevendemmie A, et al. Oxidative stress in patients affected by primary aldosteronism. J Hypertens 2014; 32:2022-2029.
29. Irita J, Okura T, Manabe S, Kurata M, Miyoshi K, Watanabe S, et al. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 2006; 19:293-297.
30. Stehr CB, Mellado R, Ocaranza MP, Carvajal CA, Mosso L, Becerra E, et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010; 28:2120-2126.
31. Acevedo M, Varleta P, Kramer V, Valentino G, Quiroga T, Prieto C, et al. Comparison of lipoprotein-Associated phospholipase A2 and high sensitive C-reactive protein as determinants of metabolic syndrome in subjects without coronary heart disease: in search of the best predictor. Int J Endocrinol 2015; 2015:1-7.
32. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1-Receptor physiology. Crit Care 2003; 7:427.
33. Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail 2013; 6:47-52.
34. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85.
35. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci 2009; 116:257-263.
36. Bar-Shalom D, Poulsen MK, Rasmussen LM, Diederichsen AC, Sand NP, Henriksen JE, et al. Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients. Diab Vasc Dis Res 2014; 11:448-450.
37. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism the German Conn's Registry. Hypertension 2012; 60:618-624.
38. Kimura T, Yamamoto T, Ohta M, Ota K, Shoji M, Funyu T, et al. Impaired vasopressin suppression and enhanced atrial natriuretic hormone release following an acute water load in primary aldosteronism. Eur J Endocrinol 1997; 137:154-161.
39. McKenna K, Thompson C. Osmoregulation in clinical disorders of thirst appreciation. Clin Endocrinol (Oxf) 1998; 49:139-152.
40. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976; 10:25-37.
41. Padfield PL. Vasopressin in hypertension. Am Heart J 1977; 94:531-532.
42. Inoue M, Kimura T, Ota K, Iitake K, Shoji M, Sato K, et al. Effect of vasopressin on atrial natriuretic peptide release and renal function in dogs. Am J Physiol Endocrinol Metab 1988; 255:E449-E455.
43. Kato J, Etoh T, Kitamura K, Eto T. Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. Am J Hypertens 2005; 18:354-357.